Harvard's 16 teaching hospitals have unanimously agreed to a new policy that requires routine disclosure and apology after an adverse event. The initiative follows in the footsteps of the Lexington Veterans Affairs Medical Center, which has had such a policy in place since 1987, as well as the medical liability insurer COPIC Insurance Co. and the University of Michigan Health System.
Harvard's 16 teaching hospitals have unanimously agreed to a new policy that requires routine disclosure and apology after an adverse event. The initiative follows in the footsteps of the Lexington Veterans Affairs Medical Center, which has had such a policy in place since 1987, as well as the medical liability insurer COPIC Insurance Co. and the University of Michigan Health System.
The Harvard policy creates a specific format for communicating with patients and their families after an adverse event, according to American Medical News (6/12/06). Immediately after the event, the facility and health-care professionals should acknowledge the event, express regret, take steps to minimize further patient harm, and commit to investigating why the event occurred. As a follow-up, the policy requires the disclosure of the internal investigation's results, the offering of an apology if there is an error or systems failure, and the creation of a plan to prevent a recurrence of the error. Additionally, the policy calls for emotional and institutional support of not only the patients, but also the health-care professionals involved.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More